SEC Form 4 · accession 0001104659-26-092838
Apogee Therapeutics, Inc. · APGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carl Dambkowski
Officer — Chief Medical Officer
Period of report
Aug 5, 2026
Accepted (ET)
Aug 7, 2026 · 8:00 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001974640
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 5, 2026 | M | 4,125 | $22.86 | A | 173,998 | D | |
| Common Stock | Aug 5, 2026 | S | 5,500 | $134.17 | D | 168,498 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $22.86 | Aug 5, 2026 | M | 4,125 | D | — | Dec 18, 2033 | Common Stock | 4,125 | 110,665 | D |
Explanation of responses
- F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.
- F2This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.